Opiate receptors, which are important pharmacological targets for analgesia and for the control of drug addiction, have not been cloned and their amino acid sequences are unknown. Recent work indicates that several opiate receptor subtypes are coupled to G protein second messenger systems. Therefore, it appears that these receptor subtypes are members of the rapidly growing superfamily of 7 transmembrane domain receptors. Recent advances in cloning technology, coupled with our large and rapidly growing data base on G protein-coupled receptors, have provided new pathways to the cloning of opiate receptors. In this application we propose several cloning strategies which make use of recent advances in the cloning of G protein-coupled receptors. In Phase II of this program, we plan to complete the cloning and characterization of these opiate receptor subtypes, including the development of heterologous expression systems for each isolated clone. These expression systems will provide the basis for the design and testing of selective, high affinity drugs targeted to individual human receptor subtypes.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43DA007455-01
Application #
3494523
Study Section
Special Emphasis Panel (SRCD (15))
Project Start
1991-09-30
Project End
1992-03-31
Budget Start
1991-09-30
Budget End
1992-03-31
Support Year
1
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Synaptic Pharmaceutical Corporation
Department
Type
DUNS #
City
Paramus
State
NJ
Country
United States
Zip Code
07652